Cite
MLA Citation
C. Paul et al.. “Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).” British journal of dermatology, vol. 173, n.d., pp. 1387–1399. http://access.bl.uk/ark:/81055/vdc_100028119371.0x00004c